Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tropex is an otic solution containing phenazone, developed and marketed by Rowa Pharmaceuticals. Phenazone is a pyrazolone derivative with analgesic and anti-inflammatory properties, belonging to the non-steroidal anti-inflammatory drug (NSAID) class. The product is specifically formulated as ear drops in a glycerol vehicle. It is indicated for the symptomatic relief of ear pain associated with conditions such as otitis media and for the softening of impacted earwax. The glycerol base acts as a hygroscopic agent, which helps to reduce edema and inflammation in the ear canal by drawing out moisture, while the phenazone provides local analgesic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenazone.